CN113817046A - 一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用 - Google Patents
一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用 Download PDFInfo
- Publication number
- CN113817046A CN113817046A CN202111141580.2A CN202111141580A CN113817046A CN 113817046 A CN113817046 A CN 113817046A CN 202111141580 A CN202111141580 A CN 202111141580A CN 113817046 A CN113817046 A CN 113817046A
- Authority
- CN
- China
- Prior art keywords
- recombinant collagen
- dressing
- repair
- gly
- repair dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 69
- 108010035532 Collagen Proteins 0.000 title claims abstract description 69
- 229920001436 collagen Polymers 0.000 title claims abstract description 68
- 230000008439 repair process Effects 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 title abstract description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 33
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 33
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000011550 stock solution Substances 0.000 claims description 22
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 15
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 24
- 206010052428 Wound Diseases 0.000 abstract description 23
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000008591 skin barrier function Effects 0.000 abstract description 4
- 208000028990 Skin injury Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000029663 wound healing Effects 0.000 abstract description 2
- 239000004909 Moisturizer Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001333 moisturizer Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 5
- 108010047495 alanylglycine Proteins 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 108010026333 seryl-proline Proteins 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 4
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 108010029020 prolylglycine Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 108010077515 glycylproline Proteins 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 2
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 2
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 2
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 2
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 2
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 2
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 2
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- DJXDNYKQOZYOFK-GUBZILKMSA-N (4s)-4-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-5-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-5-oxopentanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O DJXDNYKQOZYOFK-GUBZILKMSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- CQJHFKKGZXKZBC-BPNCWPANSA-N Ala-Pro-Tyr Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CQJHFKKGZXKZBC-BPNCWPANSA-N 0.000 description 1
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- GKKUBLFXKRDMFC-BQBZGAKWSA-N Asn-Pro-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O GKKUBLFXKRDMFC-BQBZGAKWSA-N 0.000 description 1
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 1
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 1
- NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 1
- ORYMMTRPKVTGSJ-XVKPBYJWSA-N Gln-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O ORYMMTRPKVTGSJ-XVKPBYJWSA-N 0.000 description 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 description 1
- YFGONBOFGGWKKY-VHSXEESVSA-N Gly-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O YFGONBOFGGWKKY-VHSXEESVSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 description 1
- QSQXZZCGPXQBPP-BQBZGAKWSA-N Gly-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CS)C(=O)O QSQXZZCGPXQBPP-BQBZGAKWSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- ZIMTWPHIKZEHSE-UWVGGRQHSA-N His-Arg-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O ZIMTWPHIKZEHSE-UWVGGRQHSA-N 0.000 description 1
- QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 description 1
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 1
- PARSHQDZROHERM-NHCYSSNCSA-N Ile-Lys-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O)N PARSHQDZROHERM-NHCYSSNCSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- VSJAPSMRFYUOKS-IUCAKERBSA-N Met-Pro-Gly Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O VSJAPSMRFYUOKS-IUCAKERBSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- WSRWHZRUOCACLJ-UWVGGRQHSA-N Pro-Gly-His Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H]1NCCC1)C1=CN=CN1 WSRWHZRUOCACLJ-UWVGGRQHSA-N 0.000 description 1
- XYHMFGGWNOFUOU-QXEWZRGKSA-N Pro-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 XYHMFGGWNOFUOU-QXEWZRGKSA-N 0.000 description 1
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 1
- UCTIUWKCVNGEFH-OBJOEFQTSA-N Pro-Val-Gly-Pro Chemical compound N([C@@H](C(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 UCTIUWKCVNGEFH-OBJOEFQTSA-N 0.000 description 1
- 108010052388 RGES peptide Proteins 0.000 description 1
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 1
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108010007513 prolyl-glycyl-prolyl-leucine Proteins 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种重组胶原蛋白、重组胶原蛋白修复敷料及其制备方法。所述重组胶原蛋白的氨基酸序列包括如SEQ ID NO:1所示氨基酸序列,该蛋白纯度高、热稳定性好。所述重组胶原蛋白修复敷料是通过将重组胶原蛋白、不同分子量的透明质酸、辅以其他保湿剂、抗炎成分配比后,通过特殊工艺的湿热灭菌处理获得。本发明的重组胶原蛋白修复敷料,无菌、无防腐剂,通过“外防内补”为伤口提供持续的湿润环境促进伤口愈合、保护创面新生组织,重建皮肤屏障功能,即可用于非慢性创面及小创口的辅助治疗,亦可用于因皮肤微环境失调引起皮肤损伤的修复,且生产工艺简单,具有极大的应用推广价值。
Description
技术领域
本发明属于生物医疗领域,具体涉及一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用。
背景技术
胶原蛋白是动物体内含量最多的结构蛋白,具有很强的生物活性及生物功能,为细胞生长提供依附和支撑,能诱导上皮细胞、纤维细胞等进行黏附、增殖和迁移,使结缔组织具有机械强度;同时,具有止血、生物相容性和生物降解性;还能改善细胞生长微环境,促进皮肤组织新陈代谢,修复皮肤屏障,能够引导机体组织再生。基于这些特征,胶原蛋白在烧伤、创伤、眼角膜疾病、保健、美容、矫形、硬组织修复、创面止血、药物传递、缓释技术等医药卫生领域有着广泛应用。目前,常见的胶原蛋白是从动物组织中利用酸、碱、酶解等方法提取而来,存在病毒隐患、应用于人体时会产生排异反应且分子量不确定等缺点和不足。本公司的前期研究成果很好的克服了这些缺陷,利用基因重组技术生产的重组人胶原蛋白,具有纯度高、安全性好、重现性好、质量稳定等优点。
透明质酸(HA)是线型直链状高分子黏多糖,由葡萄糖醛酸和N-乙酰氨基葡萄糖组成的双糖单位重复连接而成的天然高分子聚合物。分子量分布为1-3000000Da。高分子量HA长链分子间的交错连接使其具有致密的三维网状结构,其良好的成膜性能增强了皮肤的屏障功能,减少皮肤水分的流失及紫外线对表皮细胞的损伤,并对外界污染物进行有效隔离;中分子量HA的长久保湿性,提供了良好的肤感;小分子量HA透皮吸收后,能够深层锁水,促进细胞的修复。此外,透明质酸具有良好的生物可吸收性,生物相容性,粘弹性,因此被广泛应用于医学、美容领域。人类皮肤含有大量的透明质酸,因此皮肤的成熟和老化过程也随着透明质酸的含量和新陈代谢而变化,透明质酸可以改善皮肤营养代谢,使皮肤柔嫩、光滑、去皱、增加弹性、防止衰老。
皮肤是人体最大的免疫屏障,阻止微生物及有害物质的入侵,能够维持人体内环境的稳定,对身体健康起着关键作用,而伤口会对人体皮肤的完整性及连续性造成破坏。研究表明,伤口表皮细胞的迁移速度在湿润的愈合环境下较暴露的创面环境快,而无菌修复敷料可以为皮肤的修复提供湿润环境,调节PH及油脂平衡,重建皮肤微环境,为小创口或非慢性伤口的修复提供辅助治疗及护理,亦可用于因皮肤微环境失调引起的干燥、脱屑、红血丝、红斑、痤疮等皮肤损伤的修复。
申请号为202011567101.9 的中国发明专利申请公开了一种含有重组胶原蛋白的医用敷料及其制备方法,具体包括基材及修复原液,修复原液中透明质酸分子量单一、保湿效果差,该发明的使用范围仅针对面部肌肤问题,适用范围窄。
申请号为202010045488.5的中国发明专利申请公开了一种医用重组胶原蛋白喷雾及其制备方法,具体由重组胶原蛋白、透明质酸(单一分子量)、氯化钠、甘油、及缓冲液、防腐剂混合而成,产品以喷雾形式呈现,用于面部肌肤问题。该发明中对羟基苯甲酸酯(防腐剂)的使用为导致肌肤过敏的根源,安全性低。
申请号为201810153395.7的中国发明专利申请公开了一种重组胶原蛋白水凝胶创伤敷料及其制备方法和应用,具体由重组胶原蛋白、氯化钠、增稠剂和去离子水复合,经灭菌制备而成的凝胶敷料,主要用于创面的治疗。该发明未使用明显保湿成分,不能给伤口提供长久的湿润环境,不利于伤口的愈合,且肤感欠佳。
上述专利中公开的重组胶原蛋白修复敷料都存在一定的不足,透明质酸分子量单一,保湿效果差;产品无法兼顾无菌、无防腐;产品形式单一、适用范围窄、应用价值低等。
发明内容
本发明要解决的技术问题在于,第一是提供一种重组胶原蛋白,第二是提供一种含有重组胶原蛋白的修复敷料及其无菌制备方法。
本发明提供的重组胶原蛋白,该重组胶原蛋白的氨基酸序列如SEQ ID NO:1:
KREAEAGKDGPPGPAGNTGAPGSPGVSGPKGDAGQPGEKGSPGAQGPPGAPGPLGIAGITGARGLAGPPGMPGPRGSPGPQGVKGESGKPGANGLSGERGPPGPQGLPGLAGTAGEPGRDGNPGSDGLPGRDGSPGGKGDRGENGSPGAPGAPGHPGPPGPVGPAGKSGDRGESGPAGPAGAPGPAGSRGAPGPQGPRGDKGETGERGAAGIKGHRGFPGNPGAPGSPGPAGQQGAIGSPGPAGPRGPVGPSGPPGKDGTSGHPGPIGPPGPRGNRGERGSEGSPGHPGQPGPPGPPGAPGPCCGGVGAAAIAGIGGEKAGGFAPYYG
本专利提供了设计长度为328氨基酸的人胶原蛋白(SEQ ID NO:1),并根据毕赤酵母密码子的偏好性设计相应核苷酸序列(SEQ ID NO:2),将该序列插入毕赤酵母的pPIC9K-COL表达载体,通过电转化法将该表达载体转化毕赤酵母宿主菌GS115,并通过抗生素筛选获得高拷贝菌株。最后经过高密度发酵、分离、纯化获得高纯度的重组人源胶原蛋白原料。本发明的重组胶原蛋白热稳定性好,纯度高,能够满足本发明专利的无菌工艺要求。
本发明提供的编码上述重组胶原蛋白氨基酸序列的多核苷酸,所述多核苷酸的DNA序列如SEQ ID NO:2所示:
AAAAGAGAGGCTGAAGCTGGAAAAGATGGTCCTCCTGGTCCTGCTGGTAATACTGGTGCTCCTGGTAGTCCTGGTGTCAGTGGTCCTAAGGGTGACGCTGGTCAACCTGGTGAAAAGGGTTCTCCAGGTGCTCAAGGTCCACCTGGTGCTCCAGGTCCTTTGGGTATTGCTGGTATTACTGGTGCTAGAGGTTTGGCTGGTCCACCTGGTATGCCAGGTCCTAGAGGTTCTCCAGGTCCTCAAGGTGTTAAGGGTGAATCTGGTAAACCAGGTGCTAACGGTTTGTCCGGAGAGAGAGGTCCACCTGGACCACAAGGTTTGCCAGGTTTGGCTGGTACTGCTGGTGAACCTGGTAGAGATGGTAACCCAGGTTCTGATGGTTTGCCTGGTAGAGATGGTTCTCCAGGTGGTAAAGGAGATAGAGGTGAAAATGGTTCTCCAGGTGCTCCTGGTGCTCCAGGTCATCCTGGTCCACCTGGACCAGTTGGTCCTGCTGGTAAATCCGGAGATAGAGGTGAATCTGGTCCAGCTGGTCCTGCTGGTGCTCCAGGTCCTGCTGGTTCTAGAGGTGCTCCAGGTCCTCAAGGTCCAAGAGGAGATAAGGGTGAAACTGGAGAGAGAGGTGCTGCTGGTATTAAAGGTCACAGAGGTTTTCCAGGTAACCCTGGTGCTCCAGGTTCTCCAGGTCCTGCTGGTCAACAAGGTGCTATTGGTTCTCCAGGACCAGCTGGTCCTAGAGGTCCAGTTGGTCCTTCTGGTCCACCTGGTAAAGATGGTACTTCTGGTCATCCAGGTCCTATTGGTCCACCTGGTCCAAGAGGTAATAGAGGTGAAAGAGGTTCTGAGGGTTCTCCAGGTCACCCTGGTCAACCAGGTCCACCTGGTCCACCTGGAGCCCCAGGTCCTTGTTGTGGTGGTGTTGGTGCTGCAGCTATCGCAGGTATCGGAGGAGAGAAAGCAGGAGGTTTTGCCCCTTATTACGGTTAG
进一步的,利用本发明提供的胶原蛋白,本发明提供一种含有重组胶原蛋白的修复敷料及其无菌制备方法,工艺方案如下:
(1)称取一定比例的大、中、小分子量的透明质酸,于30℃~60℃去离子水中,搅拌混匀,充分溶涨。
(2)称取一定量的烟酰胺、甘油加入步骤(1),搅拌溶解。
(3)称取一定量的重组胶原蛋白,加入步骤(2),定容,获得修复敷料原液。
(4)向敷料原液中加入一定量的核黄素,调节敷料原液呈淡黄色。
(5)将步骤(4)获得的敷料原液进行过滤,除去可见异物,进行分装。
(6)将分装后的敷料液进行湿液灭菌,获得无菌的重组胶原蛋白修复敷料。
上述步骤(1)中,大分子透明质酸为分子量大于1500000Da;中分子量为500000Da~1500000Da;小分子量为100000Da~500000Da,透明质酸含量为0.5%~0.75%,其中大、中、小比例为(1-3):1:1。
上述步骤(2)中,烟酰胺含量为1%~3%,甘油含量为2%~5%。
上述步骤(3)中,所述胶原蛋白为微生物发酵技术获得的重组人胶原蛋白、重组人源化胶原蛋白、重组类胶原蛋白,分子量为30~150kDa,含量为0.01%~0.5%。
上述步骤(4)中,核黄素的含量为0.5µg/mL~1.0µg/mL。
上述步骤(5)中,过滤采用直径10µm聚丙烯或聚醚砜滤膜除去可见异物,分装形式可以为液体敷料、喷雾、面膜敷料。
上述步骤(6)中,湿热灭菌条件为118℃、16min或者121℃、8min。
与现有技术相比,本发明创新点如下:
1、本发明采用的原料中,透明质酸采用大、中、小不同分子量的配比,小分子量HA通过表皮细胞的吸收对其进行补水、锁水,大分子量HA的良好的成膜性增强了皮肤的屏障功能,防止水分蒸发的同时减少细胞毒素产生,避免炎症损伤,达到“内补外防”,为伤口提供湿润环境,促进伤口修复。
2、重组人胶原蛋白改善细胞生长微环境,促进皮肤组织新陈代谢,修复皮肤屏障,能够引导机体组织再生,促进伤口愈合。本发明应用的重组胶原蛋白热稳定性好,为湿热灭菌工艺的开发提供了可能,实现了重组胶原蛋白敷料的无菌、无防腐剂工艺,产品更安全。
3、本发明的重组胶原蛋白修复敷料为伤口提供持续的湿润环境促进伤口痊愈,同时保护创面新生组织,重建皮肤屏障功能,即可用于非慢性创面及小创口的辅助治疗,亦可用于因皮肤微环境失调引起的干燥、脱屑、红血丝、红斑、痤疮等皮肤损伤的修复,具有极大的应用价值。
附图说明
图1为各实施例的重组胶原蛋白修复敷料产品实物图。
图2为实施例1中重组胶原蛋白对细胞的增殖作用。
图3为实施例3中受试人员使用重组胶原蛋白修复敷料前和使用后2周面部红血丝变化图。
具体实施方式
实施例1
(1)称取大分子量HA 0.45g、中分子量HA 0.15g、小分子量HA 0.15g于60℃去离子水中,搅拌混匀,充分溶涨。
(2)称取烟酰胺3.0g、甘油2.0g加入步骤(1),搅拌溶解。
(3)称取重组胶原蛋白0.5g,加入步骤(2),定容至100g,获得修复敷料原液。
(4)向敷料原液中加入50µg的核黄素,调节敷料原液呈淡黄色。
(5)将步骤(4)获得的敷料原液采用10µm聚丙烯滤膜进行过滤,除去可见异物,分装于7mL的西林瓶中,每瓶分装5mL,封口、压盖。
(6)将分装后的敷料液进行118℃、16min高压灭菌,获得无菌的重组胶原蛋白修复敷料,为小创口或非慢性伤口的修复提供辅助治疗及护理。
具体的产品见图1。
实施例2
(1)称取大分子量HA 0.167g、中分子量HA 0. 167g、小分子量HA 0.167g于50℃去离子水中,搅拌混匀,充分溶涨。
(2)称取烟酰胺1.0g、甘油3.0g加入步骤(1),搅拌溶解。
(3)称取重组胶原蛋白0.15g,加入步骤(2),定容至100g,获得修复敷料原液。
(4)向敷料原液中加入75µg的核黄素,调节敷料原液呈淡黄色。
(5)将步骤(4)获得的敷料原液采用10µm聚丙烯滤膜进行过滤,除去可见异物,分装于30mL的西林瓶中,每瓶分装25mL,封口、压盖。
(6)将分装后的敷料液进行121℃、8min高压灭菌,获得无菌的重组胶原蛋白修复敷料,配备喷雾头,做为面部肌肤问题使用。
实施例3
(1)称取大分子量HA 0.3g、中分子量HA 0.1g、小分子量HA 0.1g于40℃去离子水中,搅拌混匀,充分溶涨。
(2)称取烟酰胺2.0g、甘油5.0g加入步骤(1),搅拌溶解。
(3)称取重组胶原蛋白0.3g,加入步骤(2),定容至100g,获得修复敷料原液。
(4)向敷料原液中加入100µg的核黄素,调节敷料原液呈淡黄色。
(5)将步骤(4)获得的敷料原液采用10µm聚醚砜滤膜进行过滤,除去可见异物,分装于30mL装有无纺布的西林瓶中,每瓶分装20mL,封口、压盖。
(6)将分装后的敷料液进行118℃、16min高压灭菌,获得无菌的重组胶原蛋白修复敷料,作为面部肌肤问题使用。
实施例4
为了测试本发明的修复敷料的效果,发明人对实施例1、实施例3获得的重组胶原蛋白修复敷料进行了性能测试,具体测试如下。
1、细胞增殖实验
将实施例1制备的重组胶原蛋白修复敷料按照医疗器械生物学评价第5部分:体外细胞毒性试验GB/T 16886.5-2017,采用MTT法进行细胞增殖实验,培养成纤维细胞L929,48小时后检测敷料对成纤维细胞的增殖作用。实验组细胞增殖明显,增值率为70%,具体见附图1和2。
2、将实施例3制备的产品用于面部红血丝患者,第一周每天一贴,每次敷15-20分钟,第二周两天一贴,每次敷15-20分钟。两周后,患者红血丝症状明显缓解,具体见附图3。
序列表
<110> 山东汉肽医美生物科技有限公司
<120> 一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 328
<212> PRT
<213> 人胶原蛋白(collagen protein)
<400> 1
Lys Arg Glu Ala Glu Ala Gly Lys Asp Gly Pro Pro Gly Pro Ala Gly
1 5 10 15
Asn Thr Gly Ala Pro Gly Ser Pro Gly Val Ser Gly Pro Lys Gly Asp
20 25 30
Ala Gly Gln Pro Gly Glu Lys Gly Ser Pro Gly Ala Gln Gly Pro Pro
35 40 45
Gly Ala Pro Gly Pro Leu Gly Ile Ala Gly Ile Thr Gly Ala Arg Gly
50 55 60
Leu Ala Gly Pro Pro Gly Met Pro Gly Pro Arg Gly Ser Pro Gly Pro
65 70 75 80
Gln Gly Val Lys Gly Glu Ser Gly Lys Pro Gly Ala Asn Gly Leu Ser
85 90 95
Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Leu Pro Gly Leu Ala Gly
100 105 110
Thr Ala Gly Glu Pro Gly Arg Asp Gly Asn Pro Gly Ser Asp Gly Leu
115 120 125
Pro Gly Arg Asp Gly Ser Pro Gly Gly Lys Gly Asp Arg Gly Glu Asn
130 135 140
Gly Ser Pro Gly Ala Pro Gly Ala Pro Gly His Pro Gly Pro Pro Gly
145 150 155 160
Pro Val Gly Pro Ala Gly Lys Ser Gly Asp Arg Gly Glu Ser Gly Pro
165 170 175
Ala Gly Pro Ala Gly Ala Pro Gly Pro Ala Gly Ser Arg Gly Ala Pro
180 185 190
Gly Pro Gln Gly Pro Arg Gly Asp Lys Gly Glu Thr Gly Glu Arg Gly
195 200 205
Ala Ala Gly Ile Lys Gly His Arg Gly Phe Pro Gly Asn Pro Gly Ala
210 215 220
Pro Gly Ser Pro Gly Pro Ala Gly Gln Gln Gly Ala Ile Gly Ser Pro
225 230 235 240
Gly Pro Ala Gly Pro Arg Gly Pro Val Gly Pro Ser Gly Pro Pro Gly
245 250 255
Lys Asp Gly Thr Ser Gly His Pro Gly Pro Ile Gly Pro Pro Gly Pro
260 265 270
Arg Gly Asn Arg Gly Glu Arg Gly Ser Glu Gly Ser Pro Gly His Pro
275 280 285
Gly Gln Pro Gly Pro Pro Gly Pro Pro Gly Ala Pro Gly Pro Cys Cys
290 295 300
Gly Gly Val Gly Ala Ala Ala Ile Ala Gly Ile Gly Gly Glu Lys Ala
305 310 315 320
Gly Gly Phe Ala Pro Tyr Tyr Gly
325
<210> 3
<211> 987
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
aaaagagagg ctgaagctgg aaaagatggt cctcctggtc ctgctggtaa tactggtgct 60
cctggtagtc ctggtgtcag tggtcctaag ggtgacgctg gtcaacctgg tgaaaagggt 120
tctccaggtg ctcaaggtcc acctggtgct ccaggtcctt tgggtattgc tggtattact 180
ggtgctagag gtttggctgg tccacctggt atgccaggtc ctagaggttc tccaggtcct 240
caaggtgtta agggtgaatc tggtaaacca ggtgctaacg gtttgtccgg agagagaggt 300
ccacctggac cacaaggttt gccaggtttg gctggtactg ctggtgaacc tggtagagat 360
ggtaacccag gttctgatgg tttgcctggt agagatggtt ctccaggtgg taaaggagat 420
agaggtgaaa atggttctcc aggtgctcct ggtgctccag gtcatcctgg tccacctgga 480
ccagttggtc ctgctggtaa atccggagat agaggtgaat ctggtccagc tggtcctgct 540
ggtgctccag gtcctgctgg ttctagaggt gctccaggtc ctcaaggtcc aagaggagat 600
aagggtgaaa ctggagagag aggtgctgct ggtattaaag gtcacagagg ttttccaggt 660
aaccctggtg ctccaggttc tccaggtcct gctggtcaac aaggtgctat tggttctcca 720
ggaccagctg gtcctagagg tccagttggt ccttctggtc cacctggtaa agatggtact 780
tctggtcatc caggtcctat tggtccacct ggtccaagag gtaatagagg tgaaagaggt 840
tctgagggtt ctccaggtca ccctggtcaa ccaggtccac ctggtccacc tggagcccca 900
ggtccttgtt gtggtggtgt tggtgctgca gctatcgcag gtatcggagg agagaaagca 960
ggaggttttg ccccttatta cggttag 987
Claims (9)
1. 一种重组胶原蛋白,其特征在于,该重组胶原蛋白氨基酸序列如SEQ ID NO:1所示。
2.一种编码SEQ ID NO:1所示氨基酸序列的多核苷酸,其特征在于,所述多核苷酸的DNA序列如SEQ ID NO:2所示。
3.权利要求1所述的重组胶原蛋白在制备修复敷料上的应用。
4.重组胶原蛋白修复敷料的制备方法,其特征在于,包括下列步骤:
(1)称取一定比例的大、中、小分子量的透明质酸,于30℃~60℃去离子水中,搅拌混匀,充分溶涨;
(2)称取一定量的烟酰胺、甘油加入步骤(1),搅拌溶解;
(3)称取一定量的权利要求1所述的重组胶原蛋白,加入步骤(2),定容,获得修复敷料原液;
(4)向敷料原液中加入一定量的核黄素,调节敷料原液呈淡黄色;
(5)将步骤(4)获得的敷料原液进行过滤,除去可见异物,进行分装;
(6)将分装后的敷料液进行湿液灭菌,获得无菌的重组胶原蛋白修复敷料。
5.根据权利要求4所述的重组胶原蛋白修复敷料的制备方法,其特征在于:步骤(1)中,大分子透明质酸为分子量大于1500000Da;中分子量为500000Da~1500000Da;小分子量为100000Da~500000Da,透明质酸含量为0.5%~0.75%,其中大、中、小比例为(1-3):1:1。
6.根据权利要求4所述的重组胶原蛋白修复敷料的制备方法,其特征在于:步骤(2)中,烟酰胺含量为1%~3%,甘油含量为2%~5%。
7.根据权利要求4所述的重组胶原蛋白修复敷料的制备方法,其特征在于:步骤(4)中,权利要求1所述的重组胶原蛋白分子量为30~150kDa,含量为0.01%~0.5%。
8.根据权利要求4所述的重组胶原蛋白修复敷料的制备方法,其特征在于:步骤(4)中,核黄素的含量为0.5µg/mL~1.0µg/mL。
9.根据权利要求4所述的重组胶原蛋白修复敷料的制备方法,其特征在于:步骤(6)中,湿热灭菌条件为118℃、16min或者121℃、8min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111141580.2A CN113817046A (zh) | 2021-09-28 | 2021-09-28 | 一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111141580.2A CN113817046A (zh) | 2021-09-28 | 2021-09-28 | 一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113817046A true CN113817046A (zh) | 2021-12-21 |
Family
ID=78921488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111141580.2A Pending CN113817046A (zh) | 2021-09-28 | 2021-09-28 | 一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113817046A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440319A (zh) * | 2023-05-15 | 2023-07-18 | 湖南美媛本草生物工程有限公司 | 一种医用修复水凝胶的制备方法与应用 |
CN116440023A (zh) * | 2023-04-23 | 2023-07-18 | 山东多美康生物医药有限公司 | 一种修复皮肤活性的重组胶原蛋白喷雾剂及其制备方法 |
WO2023143396A1 (zh) * | 2022-01-27 | 2023-08-03 | 西安巨子生物基因技术股份有限公司 | 高透皮吸收性肽及通过该肽的重复构建的重组胶原蛋白 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106902381A (zh) * | 2017-03-23 | 2017-06-30 | 陕西慧康生物科技有限责任公司 | 重组人源胶原蛋白原液、敷料以及它们的制备方法 |
CN109195579A (zh) * | 2016-04-01 | 2019-01-11 | 韩国比奥科斯全球公司 | 包含在细胞培养基中的白蛋白、透明质酸或胶原蛋白作为活性成分的化妆品组合物 |
CN110606896A (zh) * | 2019-01-29 | 2019-12-24 | 江苏悦智生物医药有限公司 | 重组人源III型胶原蛋白α1链及其应用 |
CN111072769A (zh) * | 2019-11-05 | 2020-04-28 | 南京艾澜德生物科技有限公司 | 重组胶原蛋白及其医用水凝胶 |
-
2021
- 2021-09-28 CN CN202111141580.2A patent/CN113817046A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109195579A (zh) * | 2016-04-01 | 2019-01-11 | 韩国比奥科斯全球公司 | 包含在细胞培养基中的白蛋白、透明质酸或胶原蛋白作为活性成分的化妆品组合物 |
US20200297613A1 (en) * | 2016-04-01 | 2020-09-24 | Biocoz Global Korea Corp. | Cosmetic composition containing, as active ingredient, albumin, hyaluronic acid or collagen in cell culture medium |
CN106902381A (zh) * | 2017-03-23 | 2017-06-30 | 陕西慧康生物科技有限责任公司 | 重组人源胶原蛋白原液、敷料以及它们的制备方法 |
CN110606896A (zh) * | 2019-01-29 | 2019-12-24 | 江苏悦智生物医药有限公司 | 重组人源III型胶原蛋白α1链及其应用 |
CN111072769A (zh) * | 2019-11-05 | 2020-04-28 | 南京艾澜德生物科技有限公司 | 重组胶原蛋白及其医用水凝胶 |
Non-Patent Citations (1)
Title |
---|
GENBANK: "XP_001163809.1", GENBANK, pages 2 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023143396A1 (zh) * | 2022-01-27 | 2023-08-03 | 西安巨子生物基因技术股份有限公司 | 高透皮吸收性肽及通过该肽的重复构建的重组胶原蛋白 |
CN116440023A (zh) * | 2023-04-23 | 2023-07-18 | 山东多美康生物医药有限公司 | 一种修复皮肤活性的重组胶原蛋白喷雾剂及其制备方法 |
CN116440319A (zh) * | 2023-05-15 | 2023-07-18 | 湖南美媛本草生物工程有限公司 | 一种医用修复水凝胶的制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113817046A (zh) | 一种重组人胶原蛋白、编码基因及其在制备修复敷料上的应用 | |
CN105473623B (zh) | 用于制备交联的透明质酸产物的方法 | |
RU2683286C2 (ru) | Способ поперечного сшивания гиалуроновой кислоты, способ приготовления инъекционного гидрогеля, гидрогель и его применение | |
EP3013865B1 (en) | Method for manufacturing a shaped cross-linked hyaluronic acid product | |
CN111150881A (zh) | 一种医用重组胶原蛋白喷雾及其制备方法 | |
JP2013502941A (ja) | 新規な充填剤としての粘弾性ゲル | |
US8530450B2 (en) | Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics | |
CN107213028A (zh) | 一种胶原蛋白植入剂及其制备方法 | |
ITPD950101A1 (it) | Processo per la preparazione di idrogel ottenuti da derivati chimici dell'acido ialuronico mediante irradiazioni ultraviolette e loro im- | |
CN113350567A (zh) | 一种基于胶原的生物相容性高分子敷料 | |
WO2015007773A1 (en) | Cross-linked hyaluronic acid, process for the preparation thereof and use thereof in the aesthetic field | |
CN107522881A (zh) | 制备单相修饰透明质酸钠凝胶的方法 | |
KR20150065861A (ko) | 변형된 히알우론산 유도체 및 이의 용도 | |
TW202128127A (zh) | 高分子量美容組合物 | |
CN110279887B (zh) | 一种多用途光子冷凝胶及其制备方法 | |
CN116396498A (zh) | 一种交联聚谷氨酸凝胶及其制备方法和应用 | |
CN113350568A (zh) | 一种基于明胶的生物相容性高分子敷料 | |
CN114404355B (zh) | 透明质酸钠凝胶及其制备方法、应用 | |
WO2015106970A1 (en) | Process for producing emd of increased stability | |
CN108578770A (zh) | 一种具有长效功能的注射医疗美容悬浮液及制备方法 | |
Devi et al. | Significance of hyaluronic acid in the biomedical field: A review | |
CN115215948B (zh) | 一种低分子的乙酰透明质酸脱羧肌肽衍生物、制备方法及应用 | |
TWI804143B (zh) | 交聯透明質酸以及其用途 | |
EP4371587A1 (en) | Method for preparation of filler containing dna fraction and filler prepared thereby | |
CN118420931A (zh) | 无交联剂残留的注射型重组胶原蛋白凝胶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |